Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Volvo Cars, the premium car maker, has revealed its distinctive approach to developing autonomous cars with the introduction of a family of four at the Detroit Motor Show.
The Hain family, from Gothenburg in Sweden, are the first people chosen to take part in a real-life autonomous drive research program using real cars, in real traffic.
“We do things differently at Volvo Cars – we always have,” said Håkan Samuelsson, President & CEO, Volvo Car Group. “Our main focus has always been on people and making their lives easier.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8017451-volvo-cars-develop-autonomous-cars/
